Sugi Predict

Sugi Predict / Compounds / SCHEMBL18282152

SCHEMBL18282152

SCHEMBL18282152

COC(=O)c1c(-c2cc(C)nc(C)c2)c(C)nn1-c1nc(-c2cccc(Cl)c2)c(SC(C)C)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 1/20 0.34
▸ CTSA P10619 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PLA2G2A P14555 1/20 0.33
▸ FNTA P49354 1/20 0.33
▸ FNTB P49356 1/20 0.33
▸ TYMP P19971 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.33
▸ GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18282002 0.92 TDP1 (0.34) CTSAKMT2AMAPTTDP1L3MBTL1
SCHEMBL18282291 0.92 TYMP (0.36) KMT2AMAPTMAPK1FNTAFNTB
SCHEMBL18282268 0.91 FNTA (0.42) CTSAKDM4EMAPTTDP1FNTA
SCHEMBL18282045 0.91 MYC (0.36) KMT2AKDM4EMAPTL3MBTL1FNTA
SCHEMBL18282084 0.91 MEN1 (0.38) KMT2AKDM4EMAPTMAPK1TDP1
SCHEMBL18281998 0.89 XIAP (0.32) KDM4EMAPT
SCHEMBL18282126 0.88 SLC6A3 (0.36) SLC6A3CTSAKMT2AKDM4EMAPT
SCHEMBL18282229 0.88 DPP4 (0.38) CTSA
SCHEMBL18282173 0.87 FNTA (0.34) CTSAKMT2AKDM4EMAPTFNTA
SCHEMBL18282217 0.87 TSHR (0.34) CTSAKMT2AKDM4EMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases BANTAM PHARMACEUTICAL, LLC (US) 2024-11-26 — — US disclosed
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto BANTAM PHARMACEUTICAL, LLC (US) 2023-03-14 — — US disclosed
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto BANTAM PHARMACEUTICAL, LLC 2020-08-20 — — US disclosed
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases BANTAM PHARMACEUTICAL, LLC 2020-03-05 — — US disclosed
CN-110769823-A Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases 班塔姆制药有限责任公司 2020-02-07 — — CN disclosed
EP-3548024-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Bantam Pharmaceutical, LLC (US) 2019-10-09 — — EP disclosed
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EGENIX, INC. 2018-11-01 — — US disclosed
WO-2018102452-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES BANTAM PHARMACEUTICAL, LLC (US) 2018-06-07 — — WO disclosed
EP-3303332-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO Bantam Pharmaceutical, LLC (US) 2018-04-11 — — EP disclosed
WO-2016196644-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO BANTAM PHARMACEUTICAL, LLC (US) 2016-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A1, EIF4A3, EIF4B SLC6A3 3309/4885CTSA 3450/4885KMT2A 971/4885
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A3, EIF4A1, EIF4B SLC6A3 3942/4885CTSA 3777/4885KMT2A 812/4885
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases KRAS, TP53, CCNA1 SLC6A3 4514/4885CTSA 2865/4885KMT2A 2222/4885
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases KRAS, TP53, CCNA1 SLC6A3 4514/4885CTSA 2865/4885KMT2A 2222/4885
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto EIF4A1, EIF4A3, EIF4B SLC6A3 3309/4885CTSA 3450/4885KMT2A 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.